drugset / Trial / NCT00785382

Pregabalin for Postoperative Pain in Women Undergoing Breast Cancer Surgery

NCT00785382

Phase 4 Completed 62 enrolled IWK Health Centre
RandomizedParallel-groupQuadruple-blindTreatment

Summary

We hypothesize that pregabalin will decrease postoperative pain, as measured by the surrogate markers postoperative pain rating scores and postoperative opioid consumption while improving the quality of recovery following breast cancer surgery compared to placebo. The primary outcome will be postoperative pain, measured by a NRS and the quality of recovery score (QoR) in the first 24h postoperative period. Do women undergoing breast cancer surgery with general anesthesia and receiving pregabalin prior to their surgery and 12 hours later have lower NRS and a greater QoR score in the first 24 hours after their surgery than those women who received placebo?

Timeline

Start
2009-01
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 150 mg

Indications

No indication recorded.